Brilanestrant (GDC-0810)

別名:ARN-810

Brilanestrant (GDC-0810, ARN-810) is a potent ER-α binder (ER-α, IC50 = 6.1 nM; ER-β, IC50 = 8.8 nM), a full transcriptional antagonist with no agonism and displays good potency and efficacy in ER-α degradation (EC50 = 0.7 nM) and MCF-7 breast cancer cell viability (IC50 = 2.5 nM) assays with good selectivity over other nuclear hormone receptors.

Brilanestrant (GDC-0810)化学構造

CAS No. 1365888-06-7

サイズ 価格(税別) 在庫状況
JPY 22000 国内在庫あり
JPY 67000 国内在庫あり

代表番号: 045-509-1970|電子メール:[email protected]
よく尋ねられる質問

文献中Selleckの製品使用例(2)

製品安全説明書

現在のバッチを見る: S785501 DMSO] 89 mg/mL] false] Ethanol] 89 mg/mL] false] Water] Insoluble] false 純度: 99.98%
99.98

Brilanestrant (GDC-0810)関連製品

Estrogen/progestogen Receptor阻害剤の選択性比較

生物活性

製品説明 Brilanestrant (GDC-0810, ARN-810) is a potent ER-α binder (ER-α, IC50 = 6.1 nM; ER-β, IC50 = 8.8 nM), a full transcriptional antagonist with no agonism and displays good potency and efficacy in ER-α degradation (EC50 = 0.7 nM) and MCF-7 breast cancer cell viability (IC50 = 2.5 nM) assays with good selectivity over other nuclear hormone receptors.
Targets
ERα [1]
(Cell-free)
ERβ [1]
(Cell-free)
6.1 nM 8.8 nM
In Vitro
In vitro In cell-free radio-ligand competitive binding assays, GDC-0810 binds both ERα and ERβ with low nanomolar affinity[2]. GDC-0810 has little to no inhibition against CYP1A2, CYP2D6, or CYP3A4 (IC50 > 20 μM), modest inhibitory effect on CYP2C9 and CYP2C19 (IC50 = 2.2 and 3.3 μM respectively), and potent inhibition of CYP2C8 (IC50 of <0.1 μM). Selectivity of GDC-0810 over other nuclear hormone receptors is also found to be good. In transcriptional reporter assays for the mineralocorticoid (MR), progesterone-A (PR-A), progesterone (PR-B), and glucocorticoid (GR) receptors, GDC-0810 has minimal activity (IC50 > 1 μM). While in binding assays, GDC-0810 displays little activity toward the androgen receptor (AR; IC50 > 4 μM) and GR (IC50 = 0.99 μM)[1]. GDC-0810-mediated ERα depletion is dependent on the 26S proteasome. GDC-0810 antagonizes ERα ligand binding domain mutants in vitro and in vivo. In cell-free E2 competitive binding assays that was used to determine the binding of GDC-0810 to ER.WT, ER.Y537S and ER.D538G ligand binding domains, GDC-0810 retains its ability to potently displace E2 from the ligand binding domain, albeit with a slightly increased IC50 (WT: 2.6 nM vs. ER.Y537S: 5.5 nM and ER.D538G: 5.4 nM). GDC-0810 can compete the PGC1α co-activator peptide off the mutated ligand binding domain, implying that GDC-0810 is capable of driving an 'active' to 'inactive' conformational shift of mutant ER, though with a ~five-seven fold reduction in biochemical potency compared to wild-type ER[2].
細胞実験 細胞株 MCF-7 cells
濃度 --
反応時間 4 h
実験の流れ

MCF-7 cells are trypsinized and washed twice in phenol red free RPMI containing 5% charcoal dextran stripped FBS with 20 mM HEPES and NEAA and adjusted to a concentration of 200000 cells per mL with the same medium. Next, 16 μL of the cell suspension (3200 cells) is added to each well of a poly-D-lysine coated 384-well plate, and the cells are incubated at 37℃ over 4 days to allow the cells to adhere and grow. On day 4, a 10-point, serial 1:5 dilution of each compound is added to the cells in 16 μL at a final concentration ranging from 10−5 M to 5.12 × 10−12 M or 10−6 M to 5.12 × 10−13 M for fulvestrant. At 4 h post compound addition, the cells are fixed by adding 16 μL of 30% formalin to the 32 μL of cells and compound (10% formalin final concentration) for 20 min. Cells are then washed twice with PBS Tween 0.1% and then permeabilized in PBS 0.1% Triton (50 μL/well) for additional 15 min. The PBS 0.1% triton is decanted, and the cells are washed: LI-COR blocking buffer (50 μL/well) was added, the plate is spun at 3000 rpm, and then the blocking buffer is decanted. Additional LI-COR blocking buffer (50 μL/well) is added, and the cells are incubated overnight at 4℃. The blocking buffer is decanted, and the cells are incubated overnight at 4℃ with SP1 anti-ER rabbit monoclonal antibody diluted 1:1000 in LI-COR blocking buffer/0.1% Tween-20. Wells, which are treated with blocking buffer with Tween but no antibody, are used as a background control. Wells are washed twice with PBS Tween 0.1% to remove free SP1 antibodies, and the cells are incubated at room temp for 60−90 min in LI-COR goat antirabbit IRDyeTM 800CW (1:1000) and DRAQ5 DNA dye diluted in LI-COR blocking buffer containing 0.1% Tween-20 and 0.01% SDS. Cells are then washed with 0.1%Tween-20/PBS three times. Plates are scanned on a LI-COR Odyssey infrared imaging system.

In Vivo
In Vivo The pharmacokinetic profile of GDC-0810 shows it is a low clearance molecule across species, with good bioavailability (40−60%). As would be expected for a lipophilic carboxylic acid, the compound is highly bound to plasma proteins (>99.5% across species) and has a low to moderate volume of distribution (Vss = 0.2−2.0 L/kg across species). GDC-0810 exhibits good bioavailability across species and displays robust activity in tamoxifen-sensitive and tamoxifen-resistant xenograft models of breast cancer[1]. GDC-0810 displays mild estrogenic activity in uterine models in vitro and in vivo[2].
動物実験 動物モデル a tamoxifen-sensitive MCF-7 xenograft model
投与量 30 and 100 mg/kg
投与経路 p.o.
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02802670 Completed
Healthy Volunteers
Genentech Inc.
May 2016 Phase 1
NCT02621957 Completed
Breast Cancer
Genentech Inc.
December 2015 Phase 1
NCT02569801 Terminated
Breast Cancer
Genentech Inc.
December 4 2015 Phase 2
NCT01823835 Terminated
Breast Cancer
Genentech Inc.
December 29 2014 Phase 1|Phase 2

化学情報

分子量 446.90 化学式

C26H20ClFN2O2

CAS No. 1365888-06-7 SDF --
Smiles CCC(=C(C1=CC=C(C=C1)C=CC(=O)O)C2=CC3=C(C=C2)NN=C3)C4=C(C=C(C=C4)F)Cl
保管

In vitro
Batch:

DMSO : 89 mg/mL ( (199.14 mM); 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Ethanol : 89 mg/mL

Water : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量 濃度 体積 分子量

投与溶液組成計算機(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)

mg/kg g μL

ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結果:

投与溶媒濃度: mg/ml;

DMSOストック溶液調製方法: mg 試薬を μL DMSOに溶解する(濃度 mg/mL, 注:濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法:Take μL DMSOストック溶液に μL PEG300,を加え、完全溶解後μL Tween 80,を加えて完全溶解させた後 μL ddH2O,を加え完全に溶解させます。

投与溶媒調製方法:μL DMSOストック溶液に μL Corn oil,を加え、完全溶解。

注意:1.ストック溶液に沈殿、混濁などがないことをご確認ください;
2.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください
Tags: Brilanestrant (GDC-0810)を買う | Brilanestrant (GDC-0810) ic50 | Brilanestrant (GDC-0810)供給者 | Brilanestrant (GDC-0810)を購入する | Brilanestrant (GDC-0810)費用 | Brilanestrant (GDC-0810)生産者 | オーダーBrilanestrant (GDC-0810) | Brilanestrant (GDC-0810)化学構造 | Brilanestrant (GDC-0810)分子量 | Brilanestrant (GDC-0810)代理店